Diffused large B cell lymphoma-NOS
Conditions
Interventions
sigle arm:Individualized Dynamic Frailty-Adjusted Therapy
Sponsors
Xi'an Jiaotong University Second Affiliated Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The subject fully understands this study, voluntarily participates, and signs the informed consent form (ICF). 2. Age >= 60 years, regardless of gender. 3. Patients pathologically diagnosed with diffuse large B-cell lymphoma (not otherwise specified, DLBCL-NOS). 4. Laboratory tests meet the following criteria: Total bilirubin (TBIL) <= 1.5 times the upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 times ULN. Imaging studies exclude severe infections.
Exclusion criteria
Exclusion criteria: 1. A history of severe allergy to any drug in the regimen (rituximab, cyclophosphamide, doxorubicin, vindesine, prednisone, lenalidomide). 2. Intolerance to any drug in the regimen. 3. Bacterial, fungal, or viral infections requiring systemic treatment within 1 week prior to the administration of the study drugs. 4. Severe cardiac disease or cardiac dysfunction, as determined by the investigator, making the use of anthracyclines unsuitable; or prior use of high-dose anthracyclines for other diseases, making it impossible to continue full-dose administration according to the study protocol. 5. Any other condition deemed by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The comprehensive complete remission rate(CR),partial remission rate(PR),and overall response rate(ORR,=PR)after 4 courses and 8 courses of treatment.;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the IACA index during the treatment;relapse free survival;overall survival;progression free survival; | — |
Countries
China
Contacts
Public ContactShan Meng
Xi'an Jiaotong University Second Affiliated Hospital
Outcome results
None listed